Jazz Pharmaceuticals (JAZZ) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Jul, 2026Executive summary
The annual general meeting (AGM) is scheduled for July 23, 2026, with several key proposals up for shareholder vote.
Shareholders of record as of May 28, 2026, are eligible to vote at the AGM.
Employees who are also shareholders are encouraged to participate in the voting process to ensure their shares are represented.
Voting matters and shareholder proposals
The board and management recommend voting "FOR" all director nominees and the other five proposals presented at the AGM.
Voting instructions were distributed via mail or electronically, with specific guidance for those using E*Trade services.
Board of directors and corporate governance
The board has nominated directors for election at the AGM and supports their approval.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Jazz Pharmaceuticals
- Strong neuroscience growth and robust pipeline progress offset oncology headwinds, supporting 2024 outlook.JAZZ
Bank of America 2025 Healthcare Conference9 Jul 2026 - Q1 2025 revenue steady at $898M; Chimerix closed; 2025 outlook affirmed despite headwinds.JAZZ
Q1 20259 Jul 2026 - Record Q3 2025 revenue, raised EPS guidance, and key FDA approvals drive future growth.JAZZ
Q3 20259 Jul 2026 - Record 2025 revenue of $4.3B and robust rare disease growth set up double-digit gains for 2026.JAZZ
Q4 20259 Jul 2026 - Lurbinectedin plus atezolizumab significantly improves survival in first-line ES-SCLC maintenance.JAZZ
Status Update9 Jul 2026 - Robust oncology advances and sleep portfolio growth drive confidence in future performance.JAZZ
Jefferies Global Healthcare Conference8 Jul 2026 - FDA-approved Ziihera delivers strong efficacy and safety for HER2-positive BTC, with broad expansion plans.JAZZ
Status Update8 Jul 2026 - Q3 2024 revenue up 9% to $1.05B, net income up 46%, and EPS outlook raised.JAZZ
Q3 20248 Jul 2026 - 2024 revenue hit $4.1B (+6% YoY); 2025 guidance targets 5% growth, led by Xywav and Epidiolex.JAZZ
Q4 20248 Jul 2026